Switching agonistic, antagonistic, and mixed transcriptional responses to 11 beta-substituted progestins by mutation of the progesterone receptor.
The study of transcription activation by a series of RU486-related 11 beta-substituted progestins revealed three types of ligands: agonists, antagonists, and a novel type of compounds that exerted a mixed activity. These ligands conferred to the human progesterone receptor (hPR) only weak activation properties despite high affinity binding and, hence, acted as agonists and, at the same time, as partial antagonists of pure agonists. When the same series of ligands was tested with mutant PRs, transcriptional activation/inactivation profiles were different from those seen with the wild-type PR, since several steroids initially classified as antagonists switched to mixed responses. One compound that acted as an antagonist for the hPR was an agonist for a mutated PR in which 15 amino acids of the hormone-binding domain were replaced by the corresponding divergent residues of the chicken homolog. In analyzing a series of steroids with wild-type and mutant PRs, we observed that a phenyl group (or a phenyl derivative) in the 11 beta position of RU486-related steroids generates antagonism with hPR, but has to be bound in a critical position in the hormone-binding domain to exert its antagonistic activity. Apparently, a deviation from this positioning by mutations in the hormone-binding domain can generate mixed or even agonistic activities.
Garcia
T
T
Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, Faculté de Médecine, Strasbourg, France.
Benhamou
B
B
Gofflo
D
D
Vergezac
A
A
Philibert
D
D
Chambon
P
P
Gronemeyer
H
H
D000818:Animals; D002460:Cell Line; D002645:Chickens / Q000235:genetics; D002522:Chlorocebus aethiops; D003864:Depression, Chemical; D006367:HeLa Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007668:Kidney; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics; D015735:Mifepristone / Q000031:analogs & derivatives / Q000494:pharmacology*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D013268:Stimulation, Chemical; D013329:Structure-Activity Relationship; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects*
D011980:Receptors, Progesterone; D011993:Recombinant Fusion Proteins; D015534:Trans-Activators; D015735:Mifepristone